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Abstract
Background: Bacterial targeting of tumours is an important anti-cancer strategy. We previously showed that strain 
SL7838 of Salmonella typhimurium targets and kills cancer cells. Whether NO generation by the bacteria has a role in 
SL7838 lethality to cancer cells is explored. This bacterium has the mechanism for generating NO, but also for 
decomposing it.
Methods: Mechanism underlying Salmonella typhimurium tumour therapy was investigated through in vitro and in vivo 
studies. NO measurements were conducted either by chemical assays (in vitro) or using Biosensors (in vivo). Cancer cells 
cytotoxic assay were done by using MTS. Bacterial cell survival and tumour burden were determined using molecular 
imaging techniques.
Results: SL7838 generated nitric oxide (NO) in anaerobic cell suspensions, inside infected cancer cells in vitro and in 
implanted 4T1 tumours in live mice, the last, as measured using microsensors. Thus, under these conditions, the NO 
generating pathway is more active than the decomposition pathway. The latter was eliminated, in strain SL7842, by the 
deletion of hmp- and norV genes, making SL7842 more proficient at generating NO than SL7838. SL7842 killed cancer 
cells more effectively than SL7838 in vitro, and this was dependent on nitrate availability. This strain was also ca. 100% 
more effective in treating implanted 4T1 mouse tumours than SL7838.
Conclusions: NO generation capability is important in the killing of cancer cells by Salmonella strains.
Background
Strains of Salmonella typhimurium and other bacteria
tend to target tumours and have been used for cancer
therapy and as vehicles of gene delivery in enzyme prod-
rug therapy (GDEPT) [1-3]. In our previous GDEPT work
with a number of reductive prodrugs, including our
newly discovered 6-chloro-9-nitro-5-oxo-5H-benzo
[a]phenoxazine  (CNOB), we employed S. typhimurium
strain SL7838 (ΔsopE  and ΔaroA) to deliver the chrR6
gene to tumours. SL7838 is attenuated with enhanced
preference for tumour localization, and the chrR6-
encoded enzyme (ChrR6) possesses superior capacity to
activate reductive prodrugs [4,5]. The treatments gener-
ated a dual killing effect of tumour cells, one due to the
SL7838 bacteria themselves, and the other to the acti-
vated prodrugs [4,5].
Here we investigated the mechanism of cancer cell kill-
ing by SL7838. It is thought that competition for nutri-
ents by bacteria plays a role. However, bacteria may also
be able to produce substances that are toxic to cancer
cells. One such candidate is the nitric oxide free radical
molecule (NO). That this radical has anticancer activity is
shown by the fact that high expression levels of mamma-
lian nitric oxide synthase (iNOS), which generates NO, or
the external provision of this molecule (e.g. by nitro-aspi-
rin) arrest tumour proliferation [6-9]. Like other S. typh-
imurium  strains, SL7838 possesses nitrate and nitrite
reductases and is thus able to convert nitrate and nitrite
to NO under oxygen limitation [10]. As nitrate and nitrite
are present in mammalian body (30-150 and 0.3-20.0 μM,
respectively [11]), and tumours contain hypoxic regions
[4,12-15], SL7838 has the potential to generate NO in
tumours. However, this bacterium also possesses the
Hmp and NorV enzymes that decompose NO in order to
detoxify it. Thus, its ability to generate NO would depend
on the relative activity of these opposing pathways under
given conditions. We examined the capacity of SL7838 to
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generate NO in a variety of settings and report that NO
generation is likely to play a major role in its lethality to
cancer cells.
Methods
Bacterial strains, plasmids primers and chemicals
See  Table S1.  Salmonella typhimurium strain SL7838
was transformed by electroporation [16] with plasmids
pCGSL1, encoding the Lux operon, and pFVP25.1,
encoding ChrR6. Deletion of the norV, hmP genes (to
generate strain SL7842) was carried out as described [17],
using the specified primers and plasmids (Additional file
1); deletions were confirmed by three independent PCR
assays. The NO donor, 2-(N,N-Diethylamino)-diazeno-
late 2-oxide (DEA NONOate); nitrate, nitrite hemoglobin
and sodium dithionite were purchased from Sigma Inc.
MO; Griess reagent (for NO measurement), 4-amino-5-
methylamino-2',7' difluorofluorescein diacetate (DAF-FM
di-acetate) from Molecular Probe Inc. CA; and Sen-
soLyte™ caspase assay kit were from AnaSpec Inc. CA.
Tumour cell lines and viability assays
JC (murine mammary cancer) cells were obtained from
Cancer Research UK; 4T1 (murine mammary cancer) and
A-2780 (human ovarian cancer) and 293T (human kidney
cancer) from ATCC. MDA-MDB-435 (human breast can-
cer) was kindly supplied by Dr. Gambhir. All cells were
grown as adherent cultures in DMEM medium supple-
mented with 10% FBS and 1% pen/strep. Cell viability was
measured by MTS assay, as described [4].
Cancer cell infection and chemical exposure
Confluent cancer cells were infected with the appropriate
ba ct e ria l  st ra in [ M O I,  10;  ],  a nd aft e r i ncuba t io n ( 1 h,
37°C) were washed twice with preheated DMEM and fur-
ther incubated in DMEM plus gentamycin (1 h, 37°C; 100
μg/ml). Following another wash, the cells were suspended
in DMEM-gentamycin (10 μg/ml) and exposed to NO3
-
(150 μM), NO2
- (2 μM), or the NO donor DEA NONOate
(final NO concentration, 0.2 μM).
Probing intracellular NO
Washed cell were suspended in PBS buffer (50 μl) supple-
mented with DAF-FM-diacetate (5 μM) and incubated in
the dark for 15 min. 5 μl were spotted on a microscope
slide, air dried in the dark, and after the addition of 5 μl
Vectashield® fluorescence anti-quenching medium, were
covered by a glass cover slip. DAF-FM reacts quantita-
tively with NO to form a fluorescent benzotriazole deriv-
ative. Cells were visualized at 1000× magnification
(Olympus B×60 upright fluorescence microscope),
imaged (Hamamatsu Orca1 CCD), and pseudocolored,
with identical settings for each image (Image Pro Plus
5.0).
Oxygen and nitric oxide quantification in implanted 
tumours in live mice
O2  and NO profiles of tumours were determined in
groups of two mice, one with uninfected, the other
infected with SL7838; measurements were made at three
individual regions of each tumour (which had an average
depth of 14 mm). Clark-type NO and O2 microsensors
were used [18,19]. Microsensors were connected to a
picoammeter and polarized at +750 and -800 mV for NO
and O2  measurements, respectively. Amperometric
responses were recorded with DAQCard-AI-16XE-50
(National Instruments, Austin, TX) data acquisition sys-
tem, using the μ-profiler (Lubos Ploerecky, MPI Bremen,
Germany) software at 1s intervals. Each recording repre-
sented an average of 2,000 signals at 10 kHz frequency.
The microsensors were mounted on a 3-axis motorized
micromanipulator (MM 33; Märzhäuser, Wetzlar, Ger-
many) controlled by μ-profiler software (3564-K-024-BC;
Faulhaber Group, Schönaich, Germany) for μ-position-
ing. T umours were overlaid with low melt agarose (4%,
Sigma, Inc.), using a transparent plastic ring. The
microsensor tip was placed at the surface of the tumour
manually using a stereo microscope (Omano, Inc). The
profiles were measured beginning from the inside of the
tumour. The NO sensor has a sensitivity range of ~2 - 5
pA μM-1 and a spatial resolution of 60-80 μm; it was cali-
brated as described [18].
Treatment of implanted tumours
4T1 tumours were implanted in immunocompetent
BALB/c mice as before [5] - s.c.; 106 cell inoculum. The
resulting tumours (10-14 day post inoculation) were
injected with PBS, SL7838, or SL7842 (105CFU). Tumour
burden (by caliper) and the animal weight were deter -
mined at appropriate intervals. The tumour and the bac-
terial cells were visualized as before [5] via luminescence
due to firefly luciferase and Lux expression, respectively.
Imaging of bacterial Lux activity in anesthetized (2% iso-
flurane) mice was done in an IVIS Spectrum system (Cal-
iper, CA). In addition, imaging was performed 10 min
after intraperitoneal injection of luciferin (150 μL of 30
mg/ml solution). The signal generated after luciferin
addition (Luc expression) includes the signal due to the
bacterial Lux expression, but since the former was more
than 50 fold greater, the latter is negligible. All animal
studies were performed according to approved Stanford's
IACUC and biosafety committee protocols.
Statistical Analyses
Student T tests were performed in all statistical analysis,
except for the Kaplan-Meier survival curves, where
Logrank tests were used. P-values are indicated; values of
less than 0.05 were considered significant.Barak et al. BMC Cancer 2010, 10:146
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Results
We determined whether SL7838 cell suspensions can
generate NO. When supplied nitrate (500 μM) under par-
tial anaerobiosis, the suspensions generated NO for sev-
eral hours (Figure 1A). We next determined if SL7838 can
generate NO after infecting JC murine cancer cells. L-
NAME (20 μM) was used to inhibit the indigenous NO
generating activity of JC cells (due to iNOS), and NO for-
mation was detected by DAF-FM diacetate; the latter flu-
oresces in the presence of NO, as we confirmed
experimentally (Figure. 1BiA). Addition of nitrate or
nitrite (at serum concentrations) to SL7838-infected JC
cells generated the fluorescence signal (Figure. 1Bii and
1Biii). Similar results were obtained with infected human
MDA-MB-435 breast, or A2780 ovarian cancer cells (not
shown).
We then explored NO generation directly in implanted
s.c. 4T1 tumours in living mice after intratumoural
administration of SL7838. The tumours were impaled
with a microelectrode for NO measurement [18,19]; an
oxygen microelectrode measured oxygen concentration
in parallel. The tumours were examined at three separate
locations. In the uninfected control tumours, no NO gen-
eration was seen, and the oxygenation levels changed
with tumour depth as well as location (Figure. 2, panels
A-C) revealing, as expected, several regions of anoxia
(<~1 μM oxygen). In the infected tumours (Figure. 2,
panels D-F), NO generation of up to 300 μM was seen
(region D); the amount varied in different regions (e.g.,
lower levels in region E; none in F). Anaerobiosis tended
to be more marked in the infected tumours, but there was
no obvious correlation between the tumour oxygenation
status and NO production.
In order to test if NO generation by SL7838 contributes
to its lethality to cancer cells, we generated strain SL7842,
which was rendered more active in NO generation by
deleting the norV and hmp genes that encode the path-
ways for decomposing this radical; while SL7838 cell sus-
pensions caused complete disappearance of added NO
(90 μM) within ca. 200 min (as measured by Greiss assay),
those of SL7842 generated no decomposition; the NO
donor, DEA NONOate, was used in these experiments.
SL7848-infected 4T1 cells exhibited much greater loss of
viability than those infected with SL7838 (Figure. 3; com-
pare bars 4 and 6 from the left). The killing of the cancer
cells was dependent both on nitrate availability and bac-
terial infection. Invasion/replication assays showed that
both the strains were equally competent in invading and
replicating in cancer cells (not shown). Similar results
were obtained with JC, A2780, or 293T cancer cells (not
shown).
Strain SL7842 proved more effective also in treating
implanted 4T1 tumours in mice. Following the develop-
ment of subcutaneous (s.c.) tumours (10 - 14 days post
inoculation of 106 4T1 cells [5]), separate groups of mice
were injected intratumourally with saline (control), strain
SL7838, or SL7842. While treatment with SL7838 did
increase survival (Figure. 4A; Log Rank Test, *p <0.01) as
reported before, treatment with SL7842 generated ~100%
greater survival (Log Rank Test, **p <0.003). Similar out-
come is evident from tumour burden measurements (Fig-
ure. 4B). The bacteria remained localized to the tumour
(not shown), as revealed by bioluminescence imaging as
we previously reported ([5]; see Methods); and the mice
exhibited no significant change in weight, suggesting
non-toxicity of the treatment.
Discussion
Salmonella  bacteria are known to kill infected cancer
cells [5,21,22]. These bacteria have the capacity to gener-
ate NO, but also possess a pathway to decompose it. Since
NO is a known anti carcinogen [6-9], this investigation
addressed two questions, whether Salmonella  strain
SL7838 can generate NO under conditions found inside
Figure 1 A. NO production by SL7838 cell suspensions (A660, 1.5; 
glucose-M9 medium) incubated without shaking in the presence 
of nitrate. NO concentration was determined by the oxy-haemoglo-
bin method [24]; B. NO (green fluorescence) production in SL7838-in-
fected JC cells as measured by DAF-FM diacetate. The mammalian NO 
synthase inhibitor, L-NAME (20 μM), was added to JC cell growth me-
dium 24 h prior to bacterial infection. SL7838-infected JC cells were 
supplemented with 0.2 μM NO donor (DEA NONOate) positive control 
(i), 150 μM NO3
- (ii), or 2 μM NO2
- (iii), or none of these compounds (iv). 
Uninfected JC cells receiving 150 μM NO3
- also did not generate the 
fluorescence, as in (iv). The experiment was run in triplicate. Error bars 
represent STDEV.
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the cells and within the tumours; and whether this poten-
tial capacity has a role in cancer treatment by these bacte-
ria. Cell suspensions of this bacterium under partial
anaerobiosis generated NO, indicating that the pathway
for the formation of this radical is more active than that
involved in its decomposition. A similar result was seen
within several cancer cell lines infected with this bacte-
rium. NO was generated in the presence of LNAME,
ensuring that the mammalian iNOS was rendered inac-
tive, and no NO was generated by nitrate-supplemented
uninfected cancer cells, or the infected cancer cells not
exposed to nitrate (Figure. 1Biv). Thus, the intracellular
NO seen in these experiments was of bacterial origin and
contingent on nitrate availability. This result also shows
that Salmonella infecting these cells experience anaerobi-
osis, since oxygen is their preferred electron acceptor, and
they generate NO from nitrate (or nitrite) only under
anaerobic conditions.
We further investigated whether NO generation
occurred within the implanted 4T1 tumours in mice
Figure 2 In vivo measurement of NO, and O2 in dorsal 14-day old 4T1 subcutaneous tumours in BALB/c mice (50-100 mm3-). Symbols: Panels 
A-C: vertical NO (black circle) and oxygen (white triangle) concentration profiles in 3 different spots of an uninfected tumour; Panels D-F: such profiles 
in a tumour that was infected intratumourally with the bacteria 24 h prior to the measurement. Amperometric microsensors were used; representative 
results are presented.
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using micro sensors for both NO and oxygen. The elec-
trodes were impaled in the tumours and measurements
were made in several locations. NO generation can occur
within the tumours regardless of bacterial infection
because of mammalian nitric oxide synthases. Of these
three such enzymes, nNOS and eNOS are constitutive
but generate very low levels of NO. The enzyme responsi-
ble for most NO generation is iNOS, which requires
induction by cytokines [20]. However, no NO was
detected in the uninfected tumours, indicating lack of
activity of these enzymes. Substantial NO was seen
within the tumours infected by the bacteria, showing
once again that the bacterial infection was the cause of
NO generation. Both the distribution of NO as well as of
oxygen within the tumours was highly uneven as might
be expected form previous findings of tumour heteroge-
neity and the fact that intratumourally injected SL7838
remain confined to localized tumour regions [5].
The above results affirmed the first query of this inves-
tigation, i.e., that Salmonella SL7838 does indeed gener-
ate NO under conditions found within cancer cells and
tumours. The second question concerning the role of NO
in lethality was addressed by generating strain SL7848
with deactivated NO decomposing pathway. This strain
was more active in killing cancer cells in vitro. Further-
more, it had a vastly greater capacity to treat implanted
4T1 tumours in mice compared to strain SL7838 which
because it retains the NO decomposition pathway has
lower capacity to generate NO. We conclude that NO
generation plays an important role in anticancer activity
of  Salmonella  bacteria, and that enhancement of this
capacity can benefit cancer therapy utilizing these agents
by themselves or as vehicles of gene delivery.
Conclusions
Salmonella stains with enhanced capacity for NO genera-
tion are likely to prove beneficial in anti-cancer strategies
aimed at using these bacteria for gene delivery and cancer
treatment. Since many other bacteria can also reduce
NO3
- and NO2
- [23], this approach may prove to be gener-
ally beneficial in anti-cancer measures involving bacteria.
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Figure 3 Loss of viability at 48 h of 4T1 breast cancer cells in vitro. 
Viability loss at 48 h of 4T1 breast cancer cells in vitro with no additions 
("cells") and as a result of NO3
- (150 μM) addition with or without infec-
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Figure 4 Efficacy of bacterial treatment of implanted cancer in 
mice. A. Survival (Kaplan-Meier) curves of BALB/c mice bearing s.c. 4T1 
tumours (50-100 mm3). Symbols: untreated mice administered saline 
(control; black circle); SL7838-treated mice (black square); SL7842-
treated mice (black triangle) (n = 5 animals/group) (*p <0.015, **p < 
0.003). Bacteria (105 CFU) were administered intratumourally at the 
start of the experiment. B. Tumour burden measured at indicated time 
points using caliper. Symbols as above. T-tests *p < 0.064, **p < 0.022, 
***p < 0.035
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